Log in

Start Your Membership Now

On December 22, 2022, the U.S. Department of Justice (DOJ) published this settlement with the state of Alabama regarding the Medicaid sobriety requirement for the treatment of hepatitis C. In December 2022, the Alabama Medicaid Agency entered a settlement agreement with DOJ over the state’s policy that denied Medicaid coverage for direct-acting antiviral agents (DAA) to beneficiaries who had consumed any alcohol or illicit drugs within the six months prior to starting treatment . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Chronic Disease Management

The chronic disease management market encompasses consumers with chronic, complex conditions such as chronic kidney disease, diabetes, and heart disease. The challenges faced in this market are often compounded by the need for social services and supports. For provider organizations and health systems managing consumers with chronic conditions, a significant challenge that remains is addressing the rising cost of care for this population. As a result, payers are focusing on reducing the spend by increasing integrated models of care coordination across medical, behavioural, pharmacy, and social support systems. These new market forces are creating strategic opportunities for provider organizations that are serving this population.

Editor’s Picks

Latest Resources
See All
17% Of Japanese Adults With Chronic Pain Screen Positive For ADHD
Among Japanese adults with chronic pain, 17.1% screened positive for attention-deficit/hyperactivity disorder (ADHD), according to a recent study. The estimated ADHD prevalence among the general population of Japanese adults is 1.65%, compared to 17.1% among those with persistent chronic pain. The highest rate of ADHD-positive screenings, 27.4%, was among those who reported average pain levels of 9 or 10 on a 10-point pain severity scale. The data came from 958 adults who were first-time visitors… Read

To sign-up for monthly Chronic Disease Management alerts, you must be signed in to your account.

Government Contract Bidding Opportunities

Government Contract Award Announcements